VBIV VBI Vaccines Inc.
26,987
$0.601
$0.0011
(0.18%)
| Watchers | 26,987 |
| 52-Wk Low | $0.45 |
| 52-Wk High | $3.47 |
| Market Cap | $17.21M |
| Volume | 22,687.00 |
| 52-Wk High | $3.47 |
| 52-Wk Low | $0.45 |
VBI Vaccines Reports Full Year 2023 Financial ResultsBusiness Wire • 21 days ago
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced...
Share to Feed
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the closing of its previously...
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that it has entered into...
StockNews.com began coverage on shares of VBI Vaccines (NASDAQ:VBIV - Get Free Report) in a report released on Tuesday. The firm set a "sell" rating on the biopharmaceutical company's stock. VBI...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that David E. Anderson, Ph.D...
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI or the Company), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that it has...
StockNews.com initiated coverage on shares of VBI Vaccines (NASDAQ:VBIV Free Report) in a report issued on Monday. The firm issued a sell rating on the biopharmaceutical companys...
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results PR Newswire DURHAM...
StockNews.com assumed coverage on shares of VBI Vaccines (NASDAQ:VBIV Free Report) in a research note issued to investors on Sunday morning. The brokerage issued a sell rating on the...